Search companies

Live

AROA BIOSURGERY LIMITED (ASX: ARX)

Health care · News and insights

Price unavailable

Latest ARX announcements

Announcement Insights

AROA Secures 2027 Reimbursement Continuity While Opening a Physician-Office Route

AROA’s US reimbursement outlook has gained continuity for Symphony and a potential new channel for other products: officials confirmed Symphony’s existing outpatient rate will continue in 2027 and extend to non-sheet products in physician offices from the year’s start. The company says its primary focus remains Myriad in hospital inpatient settings, where reimbursement is unaffected. Its half-year results are due later this month, alongside a finance-chief transition scheduled for 16 November.

Updated 10 Nov 2026, 10:44 PM Sydney time
Share
SourcesUS CMS Confirms Symphony Outpatient Reimbursement RateAroa Biosurgery H1 FY27 Results & Investor EventAROA Appoints Mark Dunwoodie as CFO
Comments

Aroa Biosurgery's Symphony Reimbursement Rate Maintained for 2027

2026-11-09 · Health care

ARX: $0.505 -4.72% · MC: $179M

US Medicare and Medicaid authorities have maintained the existing outpatient reimbursement rate for Aroa Biosurgery's Symphony wound-care product for 2027. The same rate will also apply to non-sheet products in physicians' offices, which Aroa says creates an opportunity for other versions of its technology. The company's primary focus remains Myriad in hospital inpatient settings, where reimbursement is unaffected by the outpatient changes.

Updated 2026-11-09 16:19
Share
SourcesUS CMS Confirms Symphony Outpatient Reimbursement Rate
Comments

Aroa Biosurgery Sets Dates for Half-Year Results and Investor Events

2026-11-04 · Health care

ARX: $0.485 -1.02% · MC: $179M

Aroa Biosurgery will discuss its half-year results at a webinar and hold an in-person Sydney investor event later this month, covering its commercial outlook, clinical evidence and growth opportunities. The announcement follows the appointment of Mark Dunwoodie as CFO, effective later this month, as James Agnew prepares to depart.

Updated 2026-11-04 08:51
Share
SourcesAroa Biosurgery H1 FY27 Results & Investor Event
Comments

AROA Names Rakon CFO Mark Dunwoodie as Incoming Finance Chief

2026-11-03 · Health care

ARX: $0.490 +1.03% · MC: $179M

Aroa Biosurgery has appointed Mark Dunwoodie, currently CFO of NZX-listed Rakon, as its CFO and Joint Company Secretary from 16 November. The appointment is intended to support AROA’s growth strategy and an orderly handover from James Agnew, who leaves after 13 years following the half-year results and investor roadshow.

Updated 2026-11-03 08:55
Share
SourcesAROA Appoints Mark Dunwoodie as CFO
Comments